An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

NCT02565186 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2171

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: Lasmiditan

Sponsor

Eli Lilly and Company

Collaborators

[object Object]